KINASE INHIBITORS

Home Kinase Inhibitors News & Literature Highlights

Cardiovascular Toxicities of Bruton’s Tyrosine Kinase Inhibitors

This review article provides an overview of the rationale behind developing Bruton kinase inhibitors, their common cardiovascular toxicities, and associated management challenges.

Current Treatment Options in Oncology

Class Categories

Immune Checkpoint Inhibitors

Kinase Inhibitors

HER2-Targeted Therapies

Novel Immunotherapies (CAR-T, BiTE)

CARDIO-ONCOLOGY BASICS

What is Cardio-Oncology?

Link Between Cancer, Treatment, and Heart Disease

Cardio-Oncology Standards of Care

CV Evaluation of Patients Before and During Cancer Therapy

Cancer Treatment–Related Cardiotoxicity

Breast Cancer Drugs and Cardiotoxicity

Cardio-Oncology Basics: Conclusions

Meet the Faculty

Resources

General Cardio-Oncology The Cancer Patient and Cardiology

General Cardio-Oncology The Role of Cardiovascular Imaging in Cancer Patients Receiving Cardiotoxic Therapies: A Position Statement on Behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio‐Oncology Council of the European Society of Cardiology (ESC)

General Cardio-Oncology Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools From the Cardio-Oncology Study Group of the Heart Failure Association of the European Society

General Cardio-Oncology NCCN Clinical Practice Guidelines in Oncology: Survivorship Version 2.2020

General Cardio-Oncology Cardiovascular and Cancer Risk: The Role of Cardio-Oncology

Videos

Kinase Inhibitors Managing Ibrutinib-Associated Cardiotoxicity in CLL: A Case Study

Kinase Inhibitors Managing Nilotinib-Associated Cardiotoxicity in CML: A Case Study

Kinase Inhibitors Kinase Inhibitors and Cardiotoxicity: The Pharmacist Perpsective

General Cardio-Oncology Welcome Message from the Program Chair